Clinical Trial Update: A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) [Phase 1]

View source ↗

Summary

A Phase 1 trial of intravesical Enfortumab Vedotin for non-muscle invasive bladder cancer was terminated, with the study status updated accordingly.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma in Situ of the Bladder
• Non-muscle Invasive Bladder Cancer
• Urinary Bladder Neoplasms

Drugs mentioned

• Enfortumab Vedotin (enfortumab vedotin)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Urinary Bladder Neoplasms, Carcinoma in Situ | Phase 1 | Status: TERMINATED